Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × FED × pembrolizumab × Clear all

Phase

Phase 2 3 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

INDUSTRY 213 OTHER 134 NIH 7 OTHER_GOV 2 NETWORK 1 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

stenoparib 1 sargramostim 1 poly ICLC 1 pembrolizumab 1 copanlisib 1 avelumab 1 Yoga 1 Temozolomide 1 PM 01183 1 Immunoglobulins, Intravenous 1 Hydroxychloroquine 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Ethiodized Oil 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05467748 2026-01-27

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

VA Office of Research and Development

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡